Articles tagged with Weight Loss
A new trial found that increasing or decreasing sugar intake in a person's diet has no effect on their preference for sweet foods. Researchers suggest that public health advice may need to focus on reducing sugar and energy-dense foods, rather than eliminating all sweet options.
A cohort study found an association between GLP-1 receptor agonist use and chronic cough. Researchers are now seeking to confirm the link's existence, strength, and mechanisms.
Researchers identified biological markers of inflammation, liver stress, and early damage to brain cells in young adults with obesity. Low blood levels of choline, essential for liver health and long-term brain function, were also found. These findings suggest that metabolic stress and inflammation may begin far earlier than expected.
A study found that pregnant women who discontinued GLP-1 medications before or early in their pregnancy experienced higher risks of weight gain, diabetes, hypertensive disorders, and preterm delivery. Those who stopped taking the medications gained an average of 7.2 pounds more weight during pregnancy.
A new analysis by the Physicians Committee for Responsible Medicine found that a vegan diet, including
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
Researchers found that higher muscle mass combined with a lower visceral fat to muscle ratio tracks with a younger brain age. Building muscle and reducing visceral fat are actionable goals for improving brain health. The study used whole-body MRI and AI algorithms to quantify muscle volume, fat tissue, and brain age.
Combining improved diet quality with increased physical activity significantly reduces body fat, particularly visceral fat, associated with higher risks of diseases. The study found that simultaneous changes in both behaviors result in greater benefits than individual changes.
A review of 1.6 million women found that two-thirds experience excessive or inadequate weight gain during pregnancy, associated with complications such as preterm birth and large birth weight. The study supports the development of global healthy growth and weight gain standards to improve outcomes for mothers and babies worldwide.
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
Dr. Leanne Redman joins the Charles Perkins Centre to lead research on obesity, diet, and exercise, building on her extensive experience in women's health issues and translational research. With over 300 publications and numerous awards, she will expand the centre's impact on global health.
A study published in Pediatric Drugs found that children and adolescents with underweight are more likely to discontinue ADHD medication within a year. The researchers also found clear differences in dosage, gender, and age that can affect treatment outcomes.
A doctor warns of critical treatment gaps in eating disorders, highlighting the dangers of ignoring physical warning signs and behavioral indicators. Dr. Jennifer Gaudiani advocates for integrated medical and psychological care to address the urgent need for effective treatment.
A new medication called DR10624 has shown promising results in reducing high triglyceride levels by over 60% in patients with severe hypertriglyceridemia. The treatment also improved cholesterol and liver health, offering a potential alternative for managing this condition.
A new study found that combining GLP-1 receptor agonist medications with healthy lifestyle habits significantly reduces the risk of major adverse cardiovascular events, including heart attacks and strokes. The research suggests that adopting multiple healthy behaviors can lower cardiovascular risk even further.
The current NHS rollout of Mounjaro is expected to reach only around 200,000 patients in the first three years. Meanwhile, over one and a half million people are accessing private treatment for obesity. Researchers warn that strict eligibility criteria may exclude vulnerable patients from receiving treatment on the NHS.
Three new Cochrane reviews found GLP-1 drugs result in clinically meaningful weight loss, but evidence on longer-term outcomes and side effects is limited. The wider use of these drugs should consider social and commercial determinants to avoid deepening existing health inequities.
A new study finds that an AI-powered lifestyle intervention is noninferior to human coaching in achieving a composite outcome in adults with prediabetes and overweight or obesity. The AI-led Diabetes Prevention Program was noninferior to the human-led program in terms of weight reduction, physical activity, and HbA1c levels.
A new study by Beni-Suef University in Egypt reveals that nearly half of undergraduate students use non-prescription weight loss supplements without prior medical consultation. The researchers found that many users were aware of potential health risks but continued taking the supplements due to social media and family influence.
A new study found that fitness and calorie counting apps can lead to negative emotions such as shame, disappointment, and demotivation among users. The researchers called for a more holistic approach focusing on wellbeing rather than rigid calorie counting and exercise quantification.
Researchers identified a set of biomarkers that can predict blood pressure outcomes five years after adolescents underwent metabolic bariatric surgery. The study found that blood-based biomarkers were more accurate than traditional risk factors, suggesting a potential new approach to predicting long-term blood pressure outcomes.
The study found a significant increase in the use of weight loss drugs like semaglutide and tirzepatide among patients undergoing metabolic and bariatric surgery. The proportion of patients receiving these medications rose from 1.8% to 29.4% between 2020 and 2024, reflecting growing popularity and perceived effectiveness.
A new study found that adipose-derived extracellular vesicles, tiny cell messengers in obese individuals, accelerate the buildup of amyloid-β plaques in the brain, a hallmark of Alzheimer's disease. Researchers hope targeting these tiny cell messengers could reduce the risk of Alzheimer's disease in people with obesity.
The European Association for the Study of Obesity (EASO) has recommended Semaglutide and Tirzepatide as the first-line treatment for people living with obesity and most of its complications. These medications have been shown to be effective in promoting total weight loss and reducing complications such as obstructive sleep apnea, knee ...
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A study on apple cider vinegar's effectiveness in weight loss was retracted by BMJ Group due to significant methodological flaws, including implausible statistical values and inadequate reporting. The retraction was prompted by concerns raised by statisticians and experts who were unable to replicate the results.
A new study published in JAMA Network Open shows that regular phone support after losing weight is crucial for maintaining weight loss. Participants who received monthly phone calls maintained an average of 8% weight loss from their starting weight, with about 60% keeping off at least 5% of their initial weight.
A Georgia State University researcher has received a $25,000 grant to develop mechanisms for treating obesity and related metabolic dysfunctions. The goal is to identify therapeutic candidates with strong clinical translation capabilities.
The SURPASS-PEDS trial shows that tirzepatide significantly improves HbA1c levels, BMI, and fasting glucose in children aged 10-17 years with type 2 diabetes. The study demonstrates sustained improvements over a year-long period, making it a potential safe and efficacious treatment option for youth-onset type 2 diabetes.
Mayo Clinic researchers developed a genetic test that can predict how people will respond to weight loss medications. The test estimates an individual's calories to satiation, linking it to treatment success and providing personalized estimates of expected satiation threshold.
A new study uses three wearable sensors to track eating behavior and identifies five distinct patterns, including late-night snacking and stress binging. The findings lay the groundwork for personalized interventions to help individuals overcome unconscious habits that drive overeating.
New research finds that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of death and major cardiovascular events in psoriasis patients. GLP-1RAs also show promise in reducing alcohol and substance abuse, with a 65% lower risk of alcohol abuse.
A study of 92 individuals with type 2 diabetes found that those who overeat due to emotional reasons are less likely to lose clinically significant weight while taking GLP-1 receptor agonists. In contrast, individuals who eat in response to external stimuli tend to respond well to the therapy.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
A phase 3 trial of once-daily orforglipron found substantial weight loss in people with obesity but not type 2 diabetes. The medication improved cardiometabolic levels and was associated with significant reductions in body weight, waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol.
A randomised trial found that regular exercise reduced inflammation and improved endothelial function, leading to lower risk of heart attack and strokes. Exercise maintained weight loss without GLP-1 receptor agonist liraglutide.
Research suggests that semaglutide, a weight loss medication, decreases intrusive thoughts about food and improves mental health in individuals with obesity. The study found that 81% of participants experienced less food noise after taking semaglutide for at least four months.
A study of individuals taking Ozempic, Wegovy, or Mounjaro found that 21.3% reported food tasting sweeter, while 22.6% said it tasted saltier than before. These changes were linked to reduced appetite and weight loss in all groups, with participants who experienced increased sweetness being twice as likely to report increased satiety.
A national study found that half of adults without diabetes who started taking semaglutide for weight loss discontinued treatment within a year. The most common factors influencing discontinuation were age, with younger users more likely to stop, as well as high costs and higher predisposition to adverse effects.
Researchers at Penn State found that weight fluctuations and changes can lead to faster cognitive decline in older adults. The study analyzed data from 4,304 participants and showed that those with greater variability in weight experienced more rapid cognitive declines.
A cohort study shows bariatric surgery significantly lowers major metabolic comorbidity risk compared to medical weight management. The procedure is deemed a durable approach for obesity-related risk mitigation.
Despite the NHS roll-out of Mounjaro officially starting in June 2025, less than half of England has access to the weight-loss jab. An estimated 3.4 million people could benefit from tirzepatide, but only 18 out of 42 commissioning bodies have started prescribing it, leaving many patients without treatment.
A synthetic molecule called Pep19 has been shown to reduce visceral fat and improve sleep quality in overweight adults, with no side effects observed. The study involved 24 volunteers who took either a placebo or Pep19 in capsules, and found a 17% reduction in visceral fat and improved sleep quality in those who received the molecule.
A cohort study found that GLP-1 receptor agonist prescriptions are associated with a reduced risk of uveitis compared to controls. The findings suggest potential anti-inflammatory benefits beyond glycemic control, warranting further investigation into their role in ocular inflammatory diseases.
A retrospective cohort study found that approximately 1 in 10 US adults undergoing bariatric surgery initiated glucagon-like peptide-1 receptor agonists. The use of these medications was more common among women and individuals with larger body mass index regain after surgery.
A new study found that excessive visceral fat is linked to faster ageing of the heart, with a genetic predisposition to female-type fat in women potentially slowing heart ageing. Researchers also discovered that artificial intelligence analysis of images revealed signs of organ ageing, including tissue stiffness and inflammation.
A telephone-based weight loss intervention significantly reduced weight in breast cancer patients with overweight and obesity. The study suggests that this intervention may improve disease outcomes, warranting further investigation in future trials.
Researchers have developed edible microbeads that, when consumed, bind to fats in the gastrointestinal tract, potentially providing a safer and more accessible alternative to surgery or pharmaceuticals. The microbeads are made from green tea polyphenols, vitamin E, and seaweed, and show promise for weight loss in rats fed high-fat diets.
A new imaging approach allows researchers to visualize how dual-acting diabetes and obesity drugs like tirzepatide interact with cells in the pancreas and brain. The tool, called daLUXendins, provides insight into the metabolic effects triggered by these drugs, which stimulate both GLP-1R and GIPR receptors.
A new study found that adolescents with higher blood levels of per- and polyfluoroalkyl substances (PFAS) prior to bariatric surgery regained more weight and had greater increases in waist circumference up to five years after surgery. Researchers believe PFAS exposure disrupts endocrine and metabolic processes, leading to weight regain.
A systematic review and meta-analysis found that weight loss interventions before IVF increased unassisted pregnancy rates, while the effect on live births was unclear. Weight loss interventions studied included low-energy diets, exercise programs, and pharmacotherapy.
Initiation of semaglutide in adults leads to reductions in weight and cardiovascular risk factors, while increasing health care expenditures. These findings suggest potential clinical benefits, highlighting the need for long-term evaluation of semaglutide's economic impact.
Researchers found that Ozempic-induced weight loss decreased lean mass by 10% in mice, with most of the lost weight coming from non-skeletal tissues. While some skeletal muscles did shrink, others stayed the same size, and strength was affected for some but not all muscles.
Nearly 17 million teens and young adults are eligible for GLP-1RA therapy, but one in five is uninsured and nearly a third lack healthcare access, hindering treatment of cardio-kidney-metabolic diseases.
A new therapy, regulation of cues combined with behavioral weight loss (ROC+BWL), was found to be more effective than standard cognitive behavioral therapy in reducing binge eating among veterans. The benefits were sustained even six months after treatment ended.
In a randomized clinical trial, oral semaglutide significantly reduced body weight in East Asian adults with overweight or obesity, regardless of type 2 diabetes presence. The study's safety profile is consistent with glucagon-like peptide-1 receptor agonists.
Researchers from NUS have tracked changes in gene expression and splicing patterns in skeletal muscle after a 16-week lifestyle intervention program involving supervised exercise and dietary changes. The study found that participants lost weight and improved insulin sensitivity, with specific genes showing evidence of G x L interaction.
A meta-analysis published in BMC Medicine found that patients prescribed anti-obesity medications may experience a significant weight gain after stopping their prescription. The study analyzed data from 11 randomised trials and suggests that six approved anti-obesity medications are associated with weight regain after treatment cessation.
A new study identified neurobeachin as a genetic predictor of weight loss response to GLP-1RAs. The findings have the potential to advance obesity care and provide more effective, personalized treatment options.
A new genetic test can predict adulthood obesity in early childhood, allowing for targeted preventative strategies. The test was developed using data from over five million people and found to be twice as effective as previous tests at predicting obesity risk.